世界の軽度認知障害の市場規模は、2030 年までに 29 億 6000 万ドルと予想され、予測期間中 (2022 〜 2030 ) の CAGR は 5.30% と推定されます。
軽度認知障害 (MCI) は、ほとんどの日常業務を独立して行うことができる人が、記憶喪失またはその他の認知スキル (言語または視覚/空間認知など) を喪失した段階です。MCI はさまざまな原因で発症する可能性があり、MCI を発症した人は認知症になる可能性があります。 MCI は、アルツハイマー病などの神経変性疾患の一連の病気の段階です。MCI は正常な認知に回復するか、一部の人では安定した状態を維持できます。認知症市場は、疾患の種類別、年齢別、適応症別、治療法別、地域別に分類されています。この市場をけん引する要因は、世界的な高齢者人口の増加や、軽度認知障害に関する意識の高まりなどです。ただし、特定の治療法がないことによって、軽度認知障害市場の成長が妨げられる可能性があります。
目次
TABLE OF CONTENTS
1. REPORT PROLOGUE
2. MARKET INTRODUCTION
2.1. Definition
2.2. Scope of the Study
2.2.1. Research Objective
2.2.2. Assumptions
2.2.3. Limitations
3. RESEARCH METHODOLOGY
3.1. Overview
3.2. Data Mining
3.3. Secondary Research
3.4. Primary Research
3.4.1. Primary Interviews and Information Gathering Process
3.4.2. Breakdown of Primary Respondents
3.5. Forecasting Techniques
3.6. Market Size Estimation
3.6.1. Bottom-Up Approach
3.6.2. Top-Down Approach
3.7. Data Triangulation
3.8. Validation
4. MARKET DYNAMICS
4.1. Overview
4.2. Drivers
4.3. Restraints
4.4. Opportunities
5. MARKET FACTOR ANALYSIS
5.1. Porter’s Five Forces Analysis
5.1.1. Bargaining Power of Suppliers
5.1.2. Bargaining Power of Buyers
5.1.3. Threat of New Entrants
5.1.4. Threat of Substitutes
5.1.5. Intensity of Rivalry
5.2. Value Chain Analysis
5.3. COVID-19 Impact Analysis
5.3.1. Market Impact Analysis
5.3.2. Impact on Supply Chain
5.3.3. Impact on Demand
5.3.4. Impact on R&D
5.3.5. Impact On Cognition and NPS in Dementia Patients
6. GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE
6.1. Overview
6.2. Amnestic MCI
6.3. Non-Amnestic MCI
7. GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE
7.1. Overview
7.2. Child
7.3 Adult
7.1. Geriatric
8. GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS
8.1. Overview
8.2. Lewy Body Dementia
8.3. Parkinson's Disease Dementia
8.4. Alzheimer's Disease
8.5. Vascular Dementia
8.6. Other Indications
9. GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT
9.1. Overview
9.2. Medication
9.2.1. Cholinesterase Inhibitors
9.2.2. Benzodiazepines
9.2.3. Glutamate Inhibitors
9.2.4. Antihistamines
9.2.5. Proton Pump Inhibitors
9.3. Therapy
9.3.1. Cognitive Stimulation Therapy
9.3.2. Cognitive Behavioral Therapy (CBT)
10. GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY REGION
10.1. Overview
10.2. North America
10.2.1. US
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. France
10.3.3. Italy
10.3.4. Spain
10.3.5. UK
10.3.6. Rest of Europe
10.4. Asia-Pacific
10.4.1. Japan
10.4.2. China
10.4.3. India
10.4.4. Australia
10.4.5. South Korea
10.4.6. Rest of Asia-Pacific
10.5. Rest of the World
10.5.1. Middle East & Africa
10.5.2. Latin America
11. COMPANY LANDSCAPE
11.1. Overview
11.2. Competitive Analysis
11.3. Market Share Analysis
11.4. Major Growth Strategy in the Global Mild cognitive impairment (Dementia) Market
11.5. Competitive Benchmarking
11.6. Leading Players in Terms of Number of Developments in the Global Mild cognitive impairment (Dementia) Market
11.7. Key Developments and Growth Strategies
11.7.1. New Disease Type Launch/Service Deployment
11.7.2. Merger & Acquisitions
11.7.3. Joint Ventures
11.8. Major Players Financial
11.8.1. Sales & Operating Income, 2021
11.8.2. Major Players R&D Expenditure, 2021
12. COMPANY PROFILES
12.1. Pfizer Inc.
12.1.1. Company Overview
12.1.2. Disease Types Offered
12.1.3. Financial Overview
12.1.4. Key Developments
12.1.5. SWOT Analysis
12.1.6. Key Strategies
12.2. F. Hoffmann-La Roche Ltd
12.2.1. Company Overview
12.2.2. Disease Types Offered
12.2.3. Financial Overview
12.2.4. Key Developments
12.2.5. SWOT Analysis
12.2.6. Key Strategies
12.3. Novartis AG
12.3.1. Company Overview
12.3.2. Disease Types Offered
12.3.3. Financial Overview
12.3.4. Key Developments
12.3.5. SWOT Analysis
12.3.6. Key Strategies
12.4. Accord UK Ltd
12.4.1. Company Overview
12.4.2. Disease Types Offered
12.4.3. Financial Overview
12.4.4. Key Developments
12.4.5. SWOT Analysis
12.4.6. Key Strategies
12.5. Dr. Reddy’s laboratories Ltd
12.5.1. Company Overview
12.5.2. Disease Types Offered
12.5.3. Financial Overview
12.5.4. Key Developments
12.5.5. SWOT Analysis
12.5.6. Key Strategies
12.6. Hikma Pharmaceuticals PLC
12.6.1. Company Overview
12.6.2. Disease Types Offered
12.6.3. Financial Overview
12.6.4. Key Developments
12.6.5. SWOT Analysis
12.6.6. Key Strategies
12.7. Sun Pharmaceuticals ltd
12.7.1. Company Overview
12.7.2. Disease Types Offered
12.7.3. Financial Overview
12.7.4. Key Developments
12.7.5. SWOT Analysis
12.7.6. Key Strategies
12.8. Johnson & Johnson Services, Inc.,
12.8.1. Company Overview
12.8.2. Disease Types Offered
12.8.3. Financial Overview
12.8.4. Key Developments
12.8.5. SWOT Analysis
12.8.6. Key Strategies
12.9. Teva Pharmaceutical Industries Ltd.,
12.9.1. Company Overview
12.9.2. Disease Types Offered
12.9.3. Financial Overview
12.9.4. Key Developments
12.9.5. SWOT Analysis
12.9.6. Key Strategies
12.10. Takeda Pharmaceutical Company Limited
12.10.1. Company Overview
12.10.2. Disease Types Offered
12.10.3. Financial Overview
12.10.4. Key Developments
12.10.5. SWOT Analysis
12.10.6. Key Strategies
13. APPENDIX
13.1. References
13.2. Related Reports?
LIST OF TABLES
TABLE 1 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SYNOPSIS, 2022-2030
TABLE 2 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET ESTIMATES & FORECAST, 2022-2030 (USD MILLION)
TABLE 3 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 4 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 5 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 6 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 7 NORTH AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 8 NORTH AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 9 NORTH AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 10 NORTH AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 11 US: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 12 US: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 13 US: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 14 US: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 15 CANADA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 16 CANADA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 17 CANADA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 18 CANADA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 19 EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 20 EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 21 EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 22 EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 23 GERMANY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 24 GERMANY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 25 GERMANY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 26 GERMANY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 27 UK: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 28 UK: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 29 UK: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 30 UK: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 31 FRANCE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 32 FRANCE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 33 FRANCE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 34 FRANCE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 35 ITALY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 36 ITALY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 37 ITALY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 38 ITALY: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 39 SPAIN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 40 SPAIN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 41 SPAIN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 42 SPAIN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 43 REST OF EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 44 REST OF EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 45 REST OF EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 46 REST OF EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 47 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 48 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 49 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 50 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 51 INDIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 52 INDIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 53 INDIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 54 INDIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 55 CHINA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 56 CHINA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 57 CHINA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 58 CHINA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 59 JAPAN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 60 JAPAN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 61 JAPAN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 62 JAPAN: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 63 AUSTRALIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 64 AUSTRALIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 65 AUSTRALIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 66 AUSTRALIA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 67 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 68 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 69 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 70 SOUTH KOREA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 71 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 72 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 73 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 74 REST OF ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 75 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 76 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 77 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 78 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 79 MIDDLE EAST: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 80 MIDDLE EAST: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 81 MIDDLE EAST: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 82 MIDDLE EAST: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 83 AFRICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 84 AFRICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 85 AFRICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 86 AFRICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
TABLE 87 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY DISEASE TYPE, 2022-2030 (USD MILLION)
TABLE 88 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY AGE, 2022-2030 (USD MILLION)
TABLE 89 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY INDICATIONS, 2022-2030 (USD MILLION)
TABLE 90 LATIN AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET, BY TREATMENT, 2022-2030 (USD MILLION)
LIST OF FIGURES
FIGURE 1 RESEARCH PROCESS
FIGURE 2 MARKET STRUCTURE FOR THE GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET
FIGURE 3 MARKET DYNAMICS FOR THE GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET
FIGURE 4 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY DISEASE TYPE, 2021 (%)
FIGURE 5 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY AGE, 2021 (%)
FIGURE 6 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY INDICATIONS, 2021(%)
FIGURE 7 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY TREATMENT, 2021(%)
FIGURE 8 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY REGION, 2021 (%)
FIGURE 9 NORTH AMERICA: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY REGION, 2021 (%)
FIGURE 10 EUROPE: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY REGION, 2021 (%)
FIGURE 11 ASIA-PACIFIC: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY REGION, 2021 (%)
FIGURE 12 REST OF THE WORLD: MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET SHARE, BY REGION, 2021 (%)
FIGURE 13 GLOBAL MILD COGNITIVE IMPAIRMENT (DEMENTIA) MARKET: COMPANY SHARE ANALYSIS, 2021 (%)
FIGURE 14 QIAGEN NV: KEY FINANCIALS
FIGURE 15 F. HOFFMANN-LA ROCHE LTD KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 16 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS
FIGURE 17 THERMO FISHER SCIENTIFIC, INC.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 18 THERMO FISHER SCIENTIFIC, INC.: SWOT ANALYSIS
FIGURE 19 ACCORD UK LTD.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 20 ACCORD UK LTD.: SWOT ANALYSIS
FIGURE 21 DR. REDDY’S LABORATORIES LTD.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 22 DR. REDDY’S LABORATORIES LTD.: SWOT ANALYSIS
FIGURE 23 HIKMA PHARMACEUTICALS PLC: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 24 HIKMA PHARMACEUTICALS PLC: SWOT ANALYSIS
FIGURE 25 SUN PHARMACEUTICALS LTD.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 26 SUN PHARMACEUTICALS LTD.: SWOT ANALYSIS
FIGURE 27 JOHNSON & JOHNSON SERVICES, INC.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 28 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
FIGURE 29 TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 30 TEVA PHARMACEUTICAL INDUSTRIES LTD.: SWOT ANALYSIS
FIGURE 31 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY FINANCIAL OVERVIEW SNAPSHOT
FIGURE 32 TAKEDA PHARMACEUTICAL COMPANY LIMITED: SWOT ANALYSIS
